anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Ischemia-reperfusion (I/R) leads to tissue damage in transplanted kidneys, resulting in acute kidney injury (AKI) and chronic graft dysfunction, which critically compromises transplant outcomes, such as graft loss. Linaclotide, a guanylate cyclase C agonist clinically approved as a laxative, has recently been identified to exhibit renoprotective effects in a chronic kidney disease (CKD) model. This study evaluates the therapeutic effects of linaclotide on AKI triggered by I/R in a rat model with an initial comparison with other laxatives. Here, we show that linaclotide administration resulted in substantial reduction in serum creatinine levels, reflective of enhanced renal function. Histological examination revealed diminished tubular damage, and Sirius Red staining confirmed less collagen deposition, collectively indicating preserved structural integrity and mitigation of fibrosis. Further analysis demonstrated lowered expression of TGF-β and associated fibrotic markers, α-SMA, MMP2, and TIMP1, implicating the downregulation of the fibrogenic TGF-β pathway by linaclotide. Furthermore, one day after I/R insult, linaclotide profoundly diminished macrophage infiltration and suppressed critical pro-inflammatory cytokines such as TNF, IL-1β, and IL-6, signifying its potential to disrupt initial inflammatory mechanisms integral to AKI pathology. These findings suggest that linaclotide, with its established safety profile, could extend its benefits beyond gastrointestinal issues and potentially serve as a therapeutic intervention for organ transplantation. Additionally, it could provide immediate and practical insights into selecting laxatives for managing patients with AKI or CKD, regardless of the cause, and for those receiving dialysis or transplant therapy.
An edible composition that has a chewable texture and contains at least one encapsulated component is disclosed. The encapsulated component is a heat sensitive encapsulant. The encapsulated component may be a biologically active component, a pharmaceutical component, a nutraceutical component or a microorganism. In preferred embodiments, a free-flowing mixture is obtained by grinding cookies. The free flowing mixture and a plasticizer such as oil and water are mixed with an encapsulant to obtain a formable dough or crumbly mass. The dough is shaped or formed in pieces or pellets and dried to a shelf-stable moisture content. Processing is conducted at temperature sufficently low so as to prevent thermal degradation of the encapsulant and pressures sufficiently high to enable the formation of coherent pieces.
Following entry into the study, patients will receive a single dose of oral inorganic sodium nitrate (14mmol) on two separate visits, or matching placebo, in random order (i.e. 2x nitrate visits first or 2x placebo visits first) in a cross-over fashion.
A method for treating the diseases of the joints provides for injection of platelet-enriched autologous blood plasma into the affected joint and para-articular tissues. The blood is sampled from the cubital vein of the patient. The separation solution is prepared consisting of Ficoll-400 and a component selected among Verografin, Isopaque, Urografin, Urotrast, Uropolonium, Uromiro, Nisotrast-370, Triosyl, Paque, Omnipaque or Ronpaquon. The blood is layered onto the separation mixture stated above. After the first centrifugation, the upper layer of plasma is removed, and the second centrifugation follows. The layer of platelets is collected and injected into the affected joint.
Use of Nitraria tangutorum Bobr. extracts and skin external preparations comprising the same. Specifically the use of Nitraria tangutorum Bobr. extract for manufacturing an agent selected from the group consisting of an antioxidant, a melanin synthesis inhibitor, an elastic fiber hydrolysis inhibitor, and an anti-skin aging protein expression up-regulation agent. The Nitraria tangutorum Bobr. extract, especially the Nitraria tangutorum Bobr. seeds extract, has the effects of scavenging free radical activity, inhibiting tyrosinase activity, inhibiting elastase activity and up-regulating the anti-aging protein expression in human fibroblasts, which can regulate the production of collagen in the dermis and has anti-aging effect.
Endothelial cell injury is a hallmark of IgA vasculitis (IgAV), possibly associated with various factors, including oxidative stress. Certain single nucleotide polymorphisms (SNPs) of glutathione S-transferases (GST) genes have been shown to increase susceptibility to oxidative stress. The objective of our study was to evaluate the gene polymorphisms of GSTM1, GSTT1, GSTP1, and GSTA1 in patients with IgAV. DNA was extracted from the blood of 124 children with IgAV and 168 age-matched healthy controls. A higher frequency of the GSTM1 null genotype was observed in patients with gastrointestinal (GI) system involvement compared to those without GI system involvement (51.5% vs. 28.6%, p = 0.011). Additionally, the GSTM1 null genotype was less prevalent (30.8% vs. 69.2%, p = 0.032), while the GSTP1 Val/Val genotype was significantly more prevalent in patients who developed urogenital complications (scrotal swelling) during the course of the disease (60% vs. 40%, p = 0.039). This study is the first to suggest an association between GSTM1 and GSTP1 polymorphisms and various phenotypes observed during the clinical course of IgAV in the pediatric population. However, it was performed on a national and likely single ethnic cohort, too small for definitive conclusions, so larger studies are needed to confirm this association.
PURPOSE: A composition containing fermented Curcuma aromatica Salisb. extract is provided to remove DPPH radical and ABTS radical and to suppress liver damage. CONSTITUTION: A pharmacetucialc composition for preventing and treating alcoholic liver diseases contains fermented Curcuma aromatica Salisb. extract as an active ingredient. The Curcuma aromatica Salisb. is fermented by Aspergillus sp. fungi at 150°C and 2090% of relative humidity for 1 hour to 1 week. The fermented Curcuma aromatica Salisb. extract is obtained by isolating with water including purified water, methanol, ethanol, or mixture solvent thereof. A health food for preventing and treating alcoholic liver diseases contains the ffermented Curcuma aromatica Salisb. extract as an active ingredient.
Lower Crossed Syndrome is one of common postural disorder which occurs due to the muscular imbalance. It refers to specific altered muscle activation and movement patterns along with some postural deviations. Alterations in muscle activation include overactivity of hip flexors and lower back muscles paired underactivity of abdominals and gluteus muscle. This pattern of imbalance creates dysfunction. Postural correction exercise with inner and outer core muscles are necessary. There are different traditional structural approach, functional approach and biomechanics and are presumed to lead to adjustments in the length and strength of local muscles while ignoring other related malalignments and core stability. The objective of the study will be to determine the effects of Sequential Core Stability Corrective Exercise Approach for Alignment and Muscle Function in Lower Crossed Syndrome.

It will be a randomized controlled trial. Sample size will be collected after running the pilot study. The participants will be recruited through convenient sampling technique and then allocated randomly to Groups. Outcome measures will be alignment and muscle function. Pre and post reading and after one month follow-up will be recorded. Data will be analyzed using statistical package for social sciences software version 25. After assessing normality of data by Shapiro-Wilk test, it will be decided either parametric or nonparametric test will be use within a group or between two groups.

Keywords: Alignment, Core Stability, Diaphragm, Muscular Imbalance, Muscle thickness Pelvic floor.
A power management device for implementing a workflow for low power MR patient positioning on an edge device is disclosed. The power management device changes the operating mode of the edge device from the first power mode to the second power mode after a defined time interval. The power management device also controls the edge device to capture a first image of the first scene. The power management device also determines a trigger point based on detection of a plurality of objects in the captured first image. The power management device also changes the operating mode of the edge device from the second power mode to a third power mode to control power consumption when performing a set of operations at the edge device. The operating mode of the edge device may be changed at the determined trigger point.
The present invention provides douse stranded compositions wherein each strand is modified to have a motif defined by positioning of ß-D-ribonucleosides and sugar modified nucleosides. More particularly, the present compositions comprise one strand having a gapped motif and another strand having a gapped motif, a hemimer motif, a blockmer motif, a fully modified motif, a positionally modified motif or an alternating motif. At least one of the strands has complementarity to a nucleic acid target. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In some embodiments, the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The present invention also provides methods for modulating gene expression.
Subject will breathe air at less than 1.3 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at less that 1.3 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
Colonic diverticulitis is a common clinical condition; about 20% of patients with colonic diverticulosis experience abdominal symptoms and, eventually, complications such as episodes of diverticulitis or bleeding. The distinction between patients with uncomplicated or complicated diverticulitis affects the clinical management: medical therapy for the first, interventional therapy for the latter. CT imaging with intravenous contrast has become the gold standard in the diagnosis and staging of patients with suspected acute diverticulitis but, unfortunately, CT involves radiation exposure, is expensive and has contraindications. UltraSound (US) is a real-time dynamic examination with wide availability and easy accessibility and may be useful in diagnosing and managing critically ill patients who cannot be moved to CT. In a recent meta-analysis, US exam performed by Radiologists showed a pooled sensitivity of 90% (vs 95% for CT, p = 0.86) and a specificity of 90% (vs 96% for CT, p = 0.04). US is increasingly used at bedside to rapidly assess patients presenting to the Emergency Department. No previous studies have investigated the diagnostic accuracy of abdominal US performed by physician at bedside as an extension of physical examination. This study evaluates the diagnostic accuracy of bedside abdominal US.
PURPOSE: A method of producing salt containing chitosan by spraying chitosan solution on salt particles without a recrystallization process is provided. It is simple as compared to prior manufacturing methods and commercially mass produces salt containing chitosan and remarkably reduces the cost of production while producing uniform quality of products. CONSTITUTION: Acid-soluble chitosan is dissolved in organic acid, or water-soluble chitosan derivatives are dissolved in water. Then, the chitosan solution is sprayed on salt having a size of 10 to 50 to meshes and then dried to give salt containing 1.5 to 5% by weight of the chitosan or chitosan derivatives. The chitosan is α-chitosan or β-chitosan having a molecular weight of 10,000 to 100,000. The organic acid is lactic acid, acetic acid or ascorbic acid. The salt is sea salt, refined salt or rock salt.
A lipstick arrangement including a casing and a protective covering. The casing including a first part including a carrier at a bottom region, a second part and a protruding element attached to the second part. Lipstick bullet is mounted on the carrier and has an elongate shape including a sloping top portion. The carrier is operatively coupled to the first part and the second part and the carrier is arranged to move in an axial direction relative to the second part in response to the first part being rotated relative to the second part. The protective covering covers the first part of the casing when applied to the casing. The lipstick bullet when completely unscrewed is exposed in such a way that the sloping top portion of the lipstick bullet faces substantially oppositely to the protruding element.
The muscular strengthening training is permformed 3 times daily as "head-ups" where the participant lies down and lifts their head anf then holds it upright during 60 seconds. This is repeated x 3 followed by 30 head-lifts. The duration of the training programme is 6 weeks.
Thirty subjects were randomly assigned (Visit 1), and weight and height will be evaluated, as body composition and blood sampling to assess glucose, liver, and kidney function. During Visit 2, and before the administration (1.2 mg/kg of weight) of a single infusion of the polyphenolic extract, glucose in the blood will be quantified (basal; with 12 hours of fasting); later, administer a load of 75 g of oral sucrose and after 30 minutes, the blood sample will begin at different intervals: 20, 40, 60, 90 and 120 minutes. The participant solves the food consumption frequency questionnaires during this procedure. A second blood sample will be taken 48 hours later (Visit 3). Finally, a urine sample will be taken to rule out acute kidney damage through the sensitive kidney damage biomarker (KIM-1). In addition, the participant will be interviewed to answer the adverse effects questionnaire.
Recommended starting dose: 1.25 mg glyburide and 250 mg metformin hydrochloride once or twice daily with meals. 

  
  


For patients with type 2 diabetes whose hyperglycemia cannot be satisfactorily managed with diet and exercise alone, the recommended starting dose is 1.25 mg glyburide and 250 mg metformin hydrochloride once a day with a meal. As initial therapy in patients with baseline HbA1c >9% or an FPG >200 mg/dL, a starting dose of 1.25 mg glyburide and 250 mg metformin hydrochloride twice daily with the morning and evening meals may be used. Dosage increases should be made in increments of 1.25 mg glyburide and 250 mg metformin hydrochloride per day every 2 weeks up to the minimum effective dose necessary to achieve adequate control of blood glucose. In clinical trials of glyburide and metformin hydrochloride tablets as initial therapy, there was no experience with total daily doses >10 mg/2000 mg per day. Glyburide and metformin hydrochloride tablets 5 mg/500 mg should not be used as initial therapy due to an increased risk of hypoglycemia.
This study will be carried our at the Mood Disorders Psychopharmacology Unit (MDPU), University Health Network (UHN), University of Toronto, with the approval of the Research Ethics Board (REB). Informed consent will be obtained from all subjects prior to study enrollment.50 male subjects between the age of 40 and 65 will be evaluated by the psychiatrist to assess whether each patient meets DSM-IV criteria for Major Depression using the MINI and to obtain their medical and psychiatric history. In addition, the SEX FX questionnaire (an instrument measuring sexual dysfunction) will be administered. Once each patient has signed the informed consent document, the research staff will assess the severity of depressive symptoms by administering the Hamilton Depression Rating Scale (HAM-D-17). A Symptom/Side Effect Rating Scale will also be administered to measure the presence and severity of side effects that each patient may be experiencing. Each patient will then have pulse, blood pressure, weight, height, waist and hip measurements taken to evaluate their health. Patients will be asked to provide blood (about 3 teaspoons) and urine (about 1/4 cup) samples for laboratory tests (bioavailable testosterone, LH, thyroid and prolactin). The blood samples will be obtained in the morning between 0800 and 1100 hr. Each patient will then be asked to complete a series of self-report measures including the SASS, the ADAM, and the Beck Depression Inventory.The 50 healthy controls will have a structured diagnostic interview (MINI) administered by the coordinator to obtain their psychiatric and medical history. They will undergo all laboratory tests required of the depressed population and all rating scales mentioned above will be completed with this population as well. Each patient is free to withdraw from the study at any time.
Treatment will be administered on an outpatient basis. Both drugs are taken orally. Each cycle lasts 28 days. The doses of each drug will depend on when patient enters study.
Healthcare providers regularly give weight-related advice (e.g., behavioral weight loss counseling) to patients with higher weight (BMI ≥30 kg/m2). The U.S. Preventive Services Task Force recommends this practice on the basis that behavioral weight-related advice can motivate patients to attempt weight loss; however, it is also possible that this advice has adverse consequences (e.g., negative psychological reactions). In this study, we examined people's reported reactions to a recent experience of receiving weight-related advice from a healthcare provider. U.S. adults (N = 189) with higher weight who reported having received weight-related advice completed an online survey via Prolific. They answered questions about their most recent experience of receiving weight-related advice, including the purpose of the visit, characteristics of their provider, and characteristics of the advice itself. They also provided demographic information and indicated their trust in healthcare providers and the healthcare system. 90.5% of participants (n = 171) reported having one of three types of reactions to their provider's weight-related advice. Participants (1) felt motivated to change their behaviors and weight; (2) felt bad or guilty about their behaviors and weight; or (3) felt both motivated to change and bad or guilty. Using chi-square tests of independence and one-way ANOVAs, we examined how various participant characteristics and characteristics of the visit, provider, and advice itself differed across these three groups. We found significant demographic differences across the groups and found that a disproportionate amount of people in the "motivated" group reported having requested the weight-related advice and having had a two-way discussion about weight with their provider. Whereas some people feel motivated after receiving weight-related advice from a healthcare provider, others are left feeling bad about themselves or ambivalent. Understanding these varied reactions may provide insights into how healthcare providers can deliver advice that is motivating without eliciting negative psychological reactions.
The concept of ligand bias is based on the premise that different agonists can elicit distinct responses by selectively activating the same receptor. These responses often determine whether an agonist has therapeutic or undesirable effects. Therefore, it would be highly advantageous to have agonists that specifically trigger the therapeutic response. The last two decades have seen a growing trend towards the consideration of ligand bias in the development of ligands to target the κ-opioid receptor (κOR). Most of these ligands selectively favor G-protein signaling over β-arrestin signaling to potentially provide effective pain and itch relief without adverse side effects associated with κOR activation. Importantly, the specific role of β-arrestin 2 in mediating κOR agonist-induced side effects remains unknown, and similarly the therapeutic and side-effect profiles of G-protein-biased κOR agonists have not been established. Furthermore, some drugs previously labeled as G-protein-biased may not exhibit true bias but may instead be either low-intrinsic-efficacy or partial agonists. In this review, we discuss the established methods to test ligand bias, their limitations in measuring bias factors for κOR agonists, as well as recommend the consideration of other systematic factors to correlate the degree of bias signaling and pharmacological effects. This article is part of the Special Issue on "Ligand Bias".
BACKGROUND: Over the past 30 years, there have been significant advances in the understanding of the mechanisms associated with loss and recovery of consciousness following severe brain injury. This work has provided a strong grounding for the development of novel restorative therapeutic interventions. Although all interventions are aimed at modulating and thereby restoring brain function, the landscape of existing interventions encompasses a very wide scope of techniques and protocols. Despite vigorous research efforts, few approaches have been assessed with rigorous, high-quality randomized controlled trials. As a growing number of exploratory interventions emerge, it is paramount to develop standardized approaches to reporting results. The successful evaluation of novel interventions depends on implementation of shared nomenclature and infrastructure. To address this gap, the Neurocritical Care Society's Curing Coma Campaign convened nine working groups and charged them with developing common data elements (CDEs). Here, we report the work of the Therapeutic Interventions Working Group.
METHODS: The working group reviewed existing CDEs relevant to therapeutic interventions within the National Institutes of Health National Institute of Neurological Disorders and Stroke database and reviewed the literature for assessing key areas of research in the intervention space. CDEs were then proposed, iteratively discussed and reviewed, classified, and organized in a case report form (CRF).
RESULTS: We developed a unified CRF, including CDEs and key design elements (i.e., methodological or protocol parameters), divided into five sections: (1) patient information, (2) general study information, (3) behavioral interventions, (4) pharmacological interventions, and (5) device interventions.
CONCLUSIONS: The newly created CRF enhances systematization of future work by proposing a portfolio of measures that should be collected in the development and implementation of studies assessing novel interventions intended to increase the level of consciousness or rate of recovery of consciousness in patients with disorders of consciousness.
FIELD: chemistry.SUBSTANCE: group of inventions refers to chemistry of high-molecular compounds, concerns versions of method for producing chitosan sponge, which can be used in medicine as wound coatings, haemostatic materials, matrices for fabric engineering. Chitosan sponge production method involves dissolving chitosan in an aqueous solution of acetic acid, hydrochloric acid or lactic acid. After complete dissolution of chitosan while stirring, a foaming agent is added. Foaming agent used is sodium bicarbonate, potassium bicarbonate or ammonium hydrocarbonate. Then, obtained sponge is washed from residues of acid and foaming agent, and dried jaw is dried. Components are used in mentioned ratio.EFFECT: group of inventions provides simplification of synthesis and expansion of application area of obtained sponge due to possibility of controlling speed of its production and porosity.3 cl, 7 dwg, 10 ex